Loading article...
Loading article...
Stream/Area:
-
Subject:
-
Paper ID:
10.55041/IJSREM25947
Volume:
7 |
10 |
Oct 2023
Pages:
Publication Frequency:
Monthly (12 issues per year)
License:International Journal of Scientific Research in Engineering and Management follows the Creative Commons Attribution 4.0 (CC BY 4.0) License, allowing free use and distribution with proper attribution.
Sitagliptin is an oral anti-hyperglycemic agent of the dipeptidyl peptidase-4 (DPP-4) inhibitor magnificence used inside the remedy of type-2 diabetes. It stimulates insulin release and reduces glucagon levels by inhibiting of inactivation of the incretin in a glucose-dependent manner. In 2013 it was the second best-selling drug in the U.S. This evaluation encompasses diverse analytical strategies inclusive of spectrometry, high-overall performance liquid chromatography (HPLC), liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS-MS), liquid chromatography-mass spectrometry (LC-MS), capillary electrophoresis (CE), ultra-overall performance liquid chromatography (UPLC), high-overall performance skinny layer chromatography (HPTLC) and fuel line chromatography-mass spectrometry (GC-MS) for the estimation of sitagliptin in unmarried and/or in combination.
KEYWORDS
Publication Date
10/9/2023
Peer Review Type
Double-Blind Peer Review
Review Rounds: 2
Documents
Article Views
0
Total views since publication
PDF Downloads
2
Total downloads since publication
Geographic Reach
5
Digital Preservation: This article is permanently archived on Zenodo and complies with all data preservation standards across major indexing platforms.
Plagiarism Screening
This manuscript has been checked for plagiarism using TurnitinPlagiarismChecker software.
Conflict of Interest
The authors declare no conflict of interest related to this research work.
Funding Information
No funding information available for this research.
Related research in the same subject area
Loading similar articles...